Clinical trials: sponsored by University of Oxford
TB
Study of the Safety and Immunogenicity of Bacille Calmette Guerin (BCG) Vaccine
Tuberculosis (TB) kills about three million people annually. It is estimated that one third of the world's population are latently infected with Mycobacterium tuberculosis (M.tb).
- Trial name
- NCT00654316
- Testing
- BCG
- Where
- United Kingdom
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis
A Study of 2 Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Previously Vaccinated With BCG
The dose of recombinant MVA used in the TB trials to date is relatively low compared with other trials using recombinant MVAs which have used up to 2.5 x 108pfu (A Hill, personal communication).
- Trial name
- NCT00465465
- Testing
- MVA 85A
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis
Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB.
This study is designed to evaluate the safety of MVA85A in healthy volunteers in the UK who are latently infected with M.tb. A single vaccination with MVA85A, when administeredat a dose of 5 x 107pfu intradermally, is safe in…
- Trial name
- NCT00456183
- Testing
- MVA 85A
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Oxford
TB
A Study of the Immunogenicity of M. Bovis BCG, Delivered Intradermally in Healthy Volunteers
To assess the immunogenicity of M. bovis BCG, given intrademally in the standard dose used in clinical practice and to measure the development of the immune response in the first six months after administration. M.
- Trial name
- NCT00480688
- Testing
- BCG
- Where
- United Kingdom
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Oxford
TB
A Study of the Immunogenicity of BCG, Delivered Intradermally in Healthy Volunteers
To assess the immunogenicity of M. bovis BCG (SSI strain), given intrademally in the standard dose used in clinical practice and to measure the development of the immune response in the first six months after administration. M.
- Trial name
- NCT00480714
- Testing
- BCG (SSI Strain)
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis
A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously
This is a phase I study to test the immunogenicity of a recombinant vaccine based on Modified Vaccinia Ankara (MVA) expressing the antigen 85A (from Mycobacterium tuberculosis).
- Trial name
- NCT00427453
- Testing
- MVA85A
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis
A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG
This is a phase I study to examine the safety and immunogenicity of MVA85A delivered intradermally into the deltoid region in volunteers who have recieved BCG in the past 20 years.
- Trial name
- NCT00427830
- Testing
- MVA85A
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis
A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian Volunteers
A Phase I study of the Safety and immunogenicity of MVA85A in healthy Gambian volunteers
- Trial name
- NCT00423839
- Testing
- MVA85A (Tuberculosis vaccine)
- Where
- The Gambia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis
A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.
This study is to assesss the safety and immunogenicity of vaccine based on Modified Vaccinia Ankara (MVA) expressing the 85A antigen (from Mycobacterium. tuberculosis).
- Trial name
- NCT00423566
- Testing
- MVA85A (Tuberculosis vaccine)
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria, Malaria, Falciparum
Efficacy of Combined PEV3A Virosomal Vaccine and FP9-MVA ME-TRAP Prime Boost Regimen
The purpose of this study is to test three candidate malaria vaccines in new combinations to assess their efficacy at preventing malaria infection and triggering immune responses against malaria.
- Trial name
- NCT00408668
- Testing
- PEV3A, FP9 ME-TRAP, MVA ME-TRAP
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Village Children
Deworming and Enhanced Vitamin A Every 6 Month in Rural Indian Children Aged 1-6
Randomisation of 72 large rural areas ("blocks") into a 2 x 2 trial of six- monthly treatment of all village children aged 1-5 with albendazole(400mg), vitamin A (200000 iu), both or neither.
- Trial name
- NCT00222547
- Testing
- Vitamin A, Albendazole
- Where
- India
- Volunteers
- 720,000 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Depression
An Evaluation of the Effectiveness of a Simple Marketing Intervention in Changing Student Attitudes to Depression
The purpose of this study is to determine the effectiveness of a simple marketing intervention in changing attitudes towards depression and its treatment among university students.
- Trial name
- NCT00122083
- Testing
- Health education information
- Where
- United Kingdom
- Volunteers
- 1,680 people, healthy volunteers welcome
- Sponsor
- University of Oxford